Navigation Links
Pharsight Achieves First License Sale for Public-Source Database
Date:8/27/2007

o the design and performance of the Pharsight public-source meta-database offering are forward looking statements. Forward-looking statements are inherently speculative, and actual results may differ materially from Pharsight's expectations due to a variety of factors, including: changes in FDA regulations may affect the demand for the product; and customers may not perceive the benefits of the product to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company's most recent Form 10-Q filed with the Securities and Exchange Commission on August 13, 2007. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand and product names are trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Inacom Information Systems achieves Cisco Systems Partner -Gold Certified status
2. Third Wave Achieves Milestone, Delivers 200,000 SNP Assays to RIKEN In Japan
3. The Genesis of Gendicine: The Story Behind the First Gene Therapy
4. Midwest life science stocks sizzle in a tepid first quarter
5. Morgridge Institute for Research seeks first CEO
6. Sonic Foundry reports first cash-positive quarter
7. Angel investors commit $12.7B in first half of `06
8. Aurora team implants Wisconsins first total artificial heart
9. First half of 2006 roundup: Big Pharma trumps biotech
10. GE announces first installation of Discovery VCT
11. GE Healthcare enjoys robust growth in first quarter
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3
Breaking Biology News(10 mins):New inherited eye disease discovered 2Introns: A mystery renewed 2Introns: A mystery renewed 3Introns: A mystery renewed 4Experts: Disease-resistant plants enhance profits, client satisfaction 2Olympus Managed Health Care Nominated for Prestigious International Award 57106 1Olympus Managed Health Care Nominated for Prestigious International Award 57106 2American Scientific Resources Acquires Intellectual Property to Worlds Only FDA Approved Home Needle Destruction Device 57103 1American Scientific Resources Acquires Intellectual Property to Worlds Only FDA Approved Home Needle Destruction Device 57103 2American Scientific Resources Acquires Intellectual Property to Worlds Only FDA Approved Home Needle Destruction Device 57103 3Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 28ICAAC 5001 1Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 28ICAAC 5001 2Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 28ICAAC 5001 3Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 28ICAAC 5001 4Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 28ICAAC 5001 5